.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB11_Aumolertinib.Aumolertinib

Information

name:Aumolertinib
ATC code:L01EB11
route:oral
n-compartments2

Aumolertinib is a third-generation, oral, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). It is approved in China for the treatment of patients with advanced or metastatic NSCLC harboring EGFR mutations.

Pharmacokinetics

Pharmacokinetic parameters in adult patients with advanced NSCLC following oral administration. Population PK analyses and clinical studies support the following estimates.

References

    Revisions

    Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos